ClinicalTrials.gg
RecruitingNCT07372287Updated Apr 28, 2026

A Phase III Study of CM326 in Subjects With Moderate to Severe Asthma

A Phase 3 interventional study of CM326 and Placebo in Moderate to Severe Asthma, sponsored by CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-04-28.

Sponsored by CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. (part of CSPC Pharmaceutical Group Limited) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Jan 2026; still recruiting 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
230
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 251 studies in Asthma with a site in China — 87 open to participants now, 96 under way, 15 of them phase 3. Asthma · China.

Planned enrollment
83rd of 182
230 · median 203
Started
2026
with 19 others
Phase 3
47 of 251
13 open now
Primary completion
2028-12
later than 86 of 95 live
Registered
227th of 251
by date

Among the 251 studies in Asthma with a site in China, this one is the 83rd largest by planned enrollment of the 182 interventional ones that give a count, is one of 20 that started in 2026, is one of 47 in phase 3, reaches primary completion later than 86 of the 95 other live ones, and was the 227th registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.

Browse Asthma studies →

Open to participants now

87 of the 251 studies in Asthma with a site in China are open now. Recruiting first, the newest first:

81 more — sign in →

All 87 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 251 studies in Asthma with a site in China, or all of them as a file.
02

Study summary

This study is a multi-center, randomized, double-blind, placebo-controlled Phase Ⅲ clinical study to evaluate the efficacy, safety, PK characteristics, PD effects and immunogenicity of CM326 in subjects with moderate to severe asthma.

The study consists of three periods, including an up to 4-week screening period, a 52-week double-blind randomized treatment period, and a 12-week safety follow-up period.

03

Conditions studied

  • Moderate to Severe Asthma

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Understand the study and voluntarily sign the form.
  2. Age ≥18 and ≤80 years old, male or female, weight ≥40 kg.
  3. The subject has been diagnosed with asthma for at least 1 year.
  4. Pre-bronchodilator measured ≤80% of the normal predicted value.
  5. A positive bronchodilation test within 24 months before informed consent or at screening.
  6. The subject has received medium-to-high dose ICS combined with at least one control drug, such as LABA, LAMA, LTRA, Oral , theophylline, for at least 3 months before signing the informed consent, and maintained stable treatment regimen and dosage for at least 1 month before signing the informed consent.
  7. Asthma Control Questionnaire-5 (ACQ-6) score ≥1.5.
  8. Subjects must have experienced at least one severe asthma exacerbation event within 12 months before informed consent, and have not experienced a severe asthma exacerbation event within 30 days before informed consent.
  9. ≥ 80% compliance with usual asthma controller therapy in subjects during the screening phase
  10. Voluntarily use highly effective from the time of signing the informed consent form until 3 months after the last dose.

Exclusion criteria

Exclusion Criteria:

  1. (COPD) without asthma or other lung disease that may impair lung function, as judged by the investigator.
  2. Have systemic diseases other than asthma that result in an elevated peripheral blood eosinophil count or other diseases such as helminth parasitic infections for which standard treatment is not received or does not respond.
  3. Prior disease or inflammatory treatment with biologic agents/systemic agents within 8 weeks or 5 half-lives (whichever is longer) prior to .
  4. Previous history of known or suspected immunosuppression, including a history of invasive opportunistic infection, even if the infection has resolved; or the presence of unusual frequent, recurrent, or prolonged infections.
  5. History of .
  6. The presence of any severe and/or uncontrolled medical condition that in the judgment of the investigator may affect the evaluation of the drug, including but not limited to: severe neurological disease, history of severe mental disorder, diabetes mellitus poorly controlled by intensive treatment.
  7. Active infection or acute infection requiring systemic anti-infective therapy from 4 weeks before enrollment to the time of randomization.
  8. A history of severe cardiovascular disease or abnormalities identified by 12-lead (ECG) during the screening phase.
  9. Major surgery within 8 weeks prior to informed consent requiring general anesthesia or hospitalization for > 1 day .
  10. Received biological agents with the same therapeutic purpose within 4 months or 5 half-lives (whichever is longer) before signing the informed consent.
  11. Have been enrolled in a clinical trial of any drug or medical device within 3 months before signing informed consent, or are within the follow-up period of a clinical study or the five half-lives of the trial drug (whichever is longer) before signing informed consent.
  12. Received immune globulin or blood products within 30 days before informed consent.
  13. Subjects treated with systemic other than for the treatment of asthma from 8 weeks before signing the informed consent to the date of randomization.
  14. Received live or attenuated vaccine within 3 months before informed consent.
  15. Initiation of desensitization therapy within 3 months before informed consent.
  16. Underwent bronchial thermoplasty within 12 months before informed consent.
  17. Current smokers or former smokers who quit smoking less than 6 months or former smokers who quit smoking more than 6 months with a smoking history of more than 10 pack-years.
  18. At screening, any infectious disease screening indicator meets one of the following criteria: a. positive b. HBsAg negative , HBcAb positive, HBV DNA exceed the lower limit of quantitation (LLOQ) or 1000 copies/mL (500 IU/mL)(whichever is lower) c. antibody positive, HCV RNA exceed the LLOQ or 1000 copies/mL(whichever is lowerd). d. antibody positive. e.Treponema pallidum antibody positive
  19. At screening, (AST) or alanine aminotransferase (ALT) > 2 × (ULN), or serum creatinine (Cr) > 1.5 × ULN.
  20. Allergy or intolerance to components of CM326 injection or placebo or history of severe drug allergy or anaphylactic shock.
  21. Subjects who have used heavy alcohol within 3 months before screening.
  22. History of drug abuse within 5 years before signing informed consent.
  23. Females with a positive pregnancy test, pregnant females, or lactating females.
  24. The investigator considers that there are any conditions that may prevent the subject from completing the study.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
230 participants (estimated)

Study arms

  • Experimental
    CM326

    CM326 subcutaneous (SC)

    Drug: CM326

  • Placebo comparator
    Placebo

    placebo, subcutaneous (SC)

    Other: Placebo

Interventions

  • DrugCM326

    subcutaneous injection

  • OtherPlacebo

    subcutaneous injection

06

What researchers measure

Primary outcomes

  1. Annualized rate of severe asthma exacerbations at Week 52

    Severe asthma exacerbation is defined as worsening of asthma that leads to any of the following: use of systemic corticosteroids for at least 3 days, an emergency department visit due to asthma that required systemic corticosteroids, or an inpatient hospitalization due to asthma. The annualized rate of severe asthma exacerbations is presented as the total number of exacerbations for the treatment group divided by the total duration of person follow-up.

    Time frame: week 52

Secondary outcomes

  1. Change from baseline in pre-bronchodilator forced expiratory volume in 1 second (FEV1) at Week 52

    Change from baseline in forced expiratory volume in 1 second taken before bronchodilator use will be reported.

    Time frame: week 52

  2. Annualized rate of subjects experiencing the event of loss of asthma control (LOAC) at Week 52

    A loss of asthma control (LOAC) event refers to any of the following situations experienced by the participants: continuous use of rescue medication, a decrease in FEV1 compared to baseline, an increase in ICS compared to baseline, a decrease in morning or evening PEF, or a severe asthma exacerbation.

    Time frame: week 52

  3. Annualized rate of severe asthma exacerbations associated with emergency room visit, or hospitalization at Week 52

    Severe asthma exacerbation which leads to an emergency department visit.

    Time frame: week 52

  4. Time to the first onset of the severe asthma exacerbation event

    Severe asthma exacerbation is defined as worsening of asthma that leads to any of the following: use of systemic corticosteroids for at least 3 days, an emergency department visit due to asthma that required systemic corticosteroids, and an inpatient hospitalization due to asthma. Time to first severe asthma exacerbation will be reported.

    Time frame: week 52

  5. Time to the onset of the first event of LOAC

    Time to first LOAC event will be reported.

    Time frame: week52

  6. Change from baseline in Pre-bronchodilator FEV1 percentage of predicted value (FEV1% Pred) at each evaluation time point

    Change from baseline in the ratio of FEV1 to the predicted value taken before bronchodilator use will be reported.

    Time frame: week 52

  7. Change from baseline in Pre-bronchodilator Forced vital capacity (FVC) at each evaluation time point

    Change from baseline in forced vital capacity taken before bronchodilator use will be reported.

    Time frame: week 52

  8. Change from baseline in Pre-bronchodilator Maximal Mid-Expiratory FlowForced Expiratory Flow (MMEF) at each evaluation time point

    Change from baseline in maximal mid-expiratory flow taken before bronchodilator use will be reported.

    Time frame: week 52

  9. Change from baseline in post-bronchodilator FEV1 at each evaluation time point

    Change from baseline in forced expiratory volume in 1 second taken after bronchodilator use will be reported.

    Time frame: week 52

  10. Change from baseline in weekly mean morning and evening peak expiratory flow (PEF) at each evaluation time

    The mean weekly daytime PEF is calculated as the average of daytime PEF measurements from Day -6 through the visit day. The mean weekly nocturnal PEF is calculated as the average of nighttime PEF measurements from Day -7 through Day -1 prior to the visit.

    Time frame: week 52

  11. Change from baseline in the Asthma Control Questionnaire-6(ACQ-6) score at each evaluation time point

    Asthma Control Questionnaire-6(ACQ-6) is a questionnaire consisting of 6 questions used to evaluate the degree of asthma control in the past week. The score of each question ranges from 0 to 6 (on a 7-point scale), with a higher score indicating poorer symptom control. The mean ACQ-6 score is the mean of the 6 questions.

    Time frame: week 52

  12. Proportion of participants with an ACQ-6 Score improvement of ≥0.5 points from baseline at each evaluation time point

    Individual changes of at least 0.5 are considered to be clinically meaningful, and a decrease of at least 0.5 is the responder definition for ACQ-6.

    Time frame: week 52

  13. Change from baseline in the Standardized Asthma Quality of Life Questionnaire (AQLQ(S)+12) score at each evaluation time point

    Asthma Quality of Life Questionnaire (AQLQ(S)+12)is a questionnaire consisting of 32 questions used to evaluate the quality of life of asthma participants in the past 2 weeks. Each question is scored from 1 to 7 (on a 7-point scale) based on the severity, with a higher score indicating better quality of life.

    Time frame: week 52

  14. Proportion of participants with an (AQLQ(S)+12) Score improvement of ≥0.5 points from baseline at each evaluation time point

    The responder definition for AQLQ(s)+12 is 0.5-point improvement from baseline.

    Time frame: week 52

  15. Change from baseline in asthma symptom score at each evaluation time point

    The asthma symptom score comprises 10 items (5 for the morning and 5 for the night). The item scores range from "0" (no symptoms, no nocturnal awakenings, or no activity limitation) to "4" (very severe symptoms, inability to sleep, or extreme activity limitation). The daily asthma symptom diary score is the average of 10 items (the night assessment value of the previous day and the morning assessment value of the next day).

    Time frame: week 52

  16. Change from baseline in weekly mean rescue medication use at each evaluation

    Change from baseline in the average weekly dose of rescue medication will be reported.

    Time frame: week 52

  17. Change from baseline in European Quality of Life - 5 Dimensions 5 Levels Questionnaire (EQ-5D-5L) score at each evaluation time point

    The European Quality of Life - 5 Dimensions 5 Levels Questionnaire (EQ-5D-5L) questionnaire assesses 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 response options (no problems, slight problems, moderate problems, severe problems, and extreme problems), reflecting the increasing levels of difficulty. The questionnaire also includes a visual analog scale, where participants will rate their current health status within the range of 0 to 100, with 0 representing the worst imaginable health state and 100 indicated the best health state

    Time frame: week 52

  18. Incidence and severity of Adverse events (AEs)

    The severity of adverse events is recorded using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), version 6.0. The incidence of participants with adverse events (AE) will be calculated.

    Time frame: week 64

  19. Blood drug concentration of CM326

    Time frame: week 64

  20. Change from baseline fractional exhaled nitric oxide (FeNO)

    Evaluate the changes from baseline in FeNO at each visit point.

    Time frame: week 64

  21. Change from baseline in peripheral blood eosinophil

    Evaluate the changes from baseline in blood eosinophil count at each visit point.

    Time frame: week 64

  22. Change from baseline in total serum IgE

    Evaluate the changes from baseline in total serum IgE at each visit point.

    Time frame: week 64

  23. Change from baseline in interleukin-5

    Evaluate the changes from baseline in blood serum IgE at each visit point.

    Time frame: week 64

  24. Incidence of anti-drug antibodies (ADAs)

    Time frame: week 64

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Dec 2028, 35 months after the start.

Of 173 industry-sponsored phase 3 interventional studies under Asthma, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 41. This study's planned 35 months is above that.

Counting every sponsor, half of 205 studies reached it within 27 months; a quarter within 14 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 11, 2026
First posted
Jan 28, 2026
StartActual
Jan 23, 2026
Primary completionEst.
Dec 31, 2028
CompletionEst.
Mar 31, 2029
Last update
Apr 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07372287
Responsible party
Sponsor
First posted
Jan 28, 2026
Start date
Jan 23, 2026
Primary completion
Dec 31, 2028 (estimated)
Completion
Mar 31, 2029 (estimated)
Last update
Apr 28, 2026

Study contacts

Clinical Trials Information Group officer
Contact
ctr-contact@cspc.cn
031169085587

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ocankitug

Start the discussion